Comments
Zydus Cadila has received final approval from the US health regulator to market minocycline hydrochloride extended release tablets used to treat acne.
The company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 45 mg, 80 mg, 90 mg, 105 mg and 135 mg, Zydus Cadila said in a BSE filing today.
It has also received tentative approval from the regulator for the tablets in 55 mg, 65 mg and 115 mg.
The company will produce the drug at its formulations manufacturing facility in Moraiya in Ahmedabad.
Minocycline hydrochloride extended release tablets are indicated to treat only inflammatory lesions of non-modular moderate to severe acne vulgaris in patients of 12 years of age or older.
The company has more than 170 approvals and has so far filed over 310 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.